CYLD and gastric cancer: In gastric cancer, Wang et al. have reported that CRAL (cisplatin resistance-associated lncRNA) functions as a ceRNA to reverse gastric cancer DDP resistance via the miR-505/CYLD (cylindromatosis)/AKT axis [125].